Trial reportAntimicrobial agents and chemotherapy2017
A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Trial report in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07146594 (Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of H. Pylori in a High Clarithromycin and Metronidazole Resistance Area), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of H. Pylori in a High Clarithromycin and Metronidazole Resistance Area
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Eradication of Helicobacter pylori With Vonoprazan-Amoxicillin Dual Therapy as an Alternative for Bismuth-Based Quadruple Therapy: A Systematic Review and Noninferiority Meta-Analysis.Journal of gastroenterology and hepatology · 2026Pooled it
- Trial
- Evolution of Amoxicillin-Based Mono-Antibiotic Regimens forMicroorganisms · 2026Review
- Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan forMicroorganisms · 2025Review
- 10-Day versus 14-day bismuth quadruple therapy for first-line eradication ofEClinicalMedicine · 2024Article
- Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies forAntibiotics (Basel, Switzerland) · 2024Article
- Novel therapeutic regimens againstFrontiers in microbiology · 2024Review
- Independent Risk Factors Predicting Eradication Failure of Hybrid Therapy for the First-Line Treatment ofMicroorganisms · 2023Article
- Comparative effectiveness of first-line therapies for eradication of antibiotic-resistantWorld journal of clinical cases · 2022Article
- Update on the first-line treatment ofTherapeutic advances in gastroenterology · 2022Review
- The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.Biomedical journal · 2021Article
- Management of Helicobacter pylori infection: The Bhubaneswar Consensus Report of the Indian Society of Gastroenterology.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2021Article
- Review
- Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Infection and drug resistance · 2021Article
- Potential of Bacterial Cellulose Chemisorbed with Anti-Metabolites, 3-Bromopyruvate or Sertraline, to Fight againstInternational journal of molecular sciences · 2020Article
- BestAntibiotics (Basel, Switzerland) · 2020Review
- Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection.Journal of the Chinese Medical Association : JCMA · 2020Article
- Trend of changes in antibiotic resistance inTherapeutic advances in gastroenterology · 2020Article
- Time to Make a Change in the Cutoff Value of Clarithromycin Resistance in the Treatment of Helicobacter pylori Infection.The American journal of gastroenterology · 2018Article
- Update on the first-line treatment forBiomarker research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hybrid therapy is a novel two-step treatment achieving a high eradication rate for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.